论文部分内容阅读
作者对有猝死潜在危险的肥厚性心肌病(HCM)患者进行了胺碘酮的电生理检查,旨在确定此项研究可否提高使用胺碘酮的安全性和预测远期效果。方法:35例HCM患者在服胺碘酮之前后接受了前瞻性电生理研究,第1次是在停全部心血管药≥5个半衰期后,第2次是在用维持量胺碘酮时。均记录了心腔内心电图及体表心电图,刺激方案与以前报告相同,测定基础间期,窦房结传导及恢复时间,心房不应期、房室不应期、文氏周长度、1:1房室传导时的最快心室率及心室不应期。胺碘酮400mg或600mg,1日2次,用7～10天,然后每天400mg维持。在治疗4±9月后或接受总量58±
The authors performed an electrophysiological study of amiodarone in patients with hypertrophic cardiomyopathy (HCM) at a potential risk of sudden death to determine if the study could improve the safety and use of amiodarone to predict long-term outcomes. Methods: 35 HCM patients underwent prospective electrophysiological studies before and after taking amiodarone, the first after stopping ≥5 half-lives of all cardiovascular drugs and the second during maintenance amiodarone use. Intracardiac electrocardiogram and body surface electrocardiogram were recorded. The stimulation protocol was the same as the previous report. The basal interphase, conduction time and recovery time of sinus node, atrial refractory period, atrial refractory period, 1 atrioventricular conduction when the fastest ventricular rate and ventricular refractory period. Amiodarone 400 mg or 600 mg twice daily for 7-10 days followed by 400 mg daily. After treatment for 4 ± 9 months or receiving a total of 58 ±